About greenwich lifesciences inc - GLSI
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
GLSI At a Glance
Greenwich LifeSciences, Inc.
3992 Bluebonnet Drive
Stafford, Texas 77477
| Phone | 1-832-819-3232 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -19,358,218.00 | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GLSI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 850.607 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -14.306 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
GLSI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,489,093.692 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GLSI Liquidity
| Current Ratio | 1.061 |
| Quick Ratio | 1.061 |
| Cash Ratio | 1.061 |
GLSI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -376.92 |
| Return on Equity | -1,340.944 |
| Return on Total Capital | -5,480.545 |
| Return on Invested Capital | -1,340.944 |
GLSI Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |